Parameters of glucose and lipid metabolism affect the occurrence of colorectal adenomas detected by surveillance colonoscopies

Yonsei Medical Journal

Volumn 58, Issue 2, 2017, Pages 347-354

  Kim, Nam Hee ^a   Suh, Jung Yul ^a   Park, Jung Ho ^a   Park, Dong Il ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Choi, Kyuyong ^a   Jung, Yoon Suk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Colorectal adenoma; Dyslipidemia; Glucose metabolism; Surveillance

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN B; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; BODY MASS; CHEMILUMINESCENCE IMMUNOASSAY; COLONOSCOPY; COLORECTAL ADENOMA; DISEASE SURVEILLANCE; EVALUATION AND FOLLOW UP; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HISTOLOGY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; QUESTIONNAIRE; TRIACYLGLYCEROL BLOOD LEVEL; ADENOMA; BLOOD; COLORECTAL NEOPLASMS; DIET RESTRICTION; METABOLISM; PROPORTIONAL HAZARDS MODEL; RISK; RISK FACTOR;

ADENOMA; APOLIPOPROTEINS B; CHOLESTEROL, LDL; COLONOSCOPY; COLORECTAL NEOPLASMS; FASTING; FEMALE; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPID METABOLISM; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; TRIGLYCERIDES;

EID: 85010703540     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2017.58.2.347     Document Type: Article

References (41)

1. Lee HS, Jeon SW. Is retroflexion helpful in detecting adenomas in the right colon?: a single center interim analysis. Intest Res 2015; 13:326-31.
2. Lin OS, Kozarek RA, Cha JM. Impact of sigmoidoscopy and colonoscopy on colorectal cancer incidence and mortality: an evidence-based review of published prospective and retrospective studies. Intest Res 2014;12:268-74.
3. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844-57.
4. Luo S, Li JY, Zhao LN, Yu T, Zhong W, Xia ZS, et al. Diabetes mellitus increases the risk of colorectal neoplasia: an updated metaanalysis. Clin Res Hepatol Gastroenterol 2016;40:110-23.
5. Kim BC, Shin A, Hong CW, Sohn DK, Han KS, Ryu KH, et al. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control 2012;23:727-35.
6. Liu CS, Hsu HS, Li CI, Jan CI, Li TC, Lin WY, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol 2010;10:51.
7. Park H, Ko SH, Lee JM, Park JH, Choi YH. Troglitazone enhances the apoptotic response of DLD-1 colon cancer cells to photodynamic therapy. Yonsei Med J 2016;57:1494-9.
8. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sandler RS. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2005;14:2076-81.
9. Rampal S, Yang MH, Sung J, Son HJ, Choi YH, Lee JH, et al. Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterology 2014;147:78-87.
10. Vidal AC, Lund PK, Hoyo C, Galanko J, Burcal L, Holston R, et al. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer 2012;12:389.
11. Ortiz AP, Thompson CL, Chak A, Berger NA, Li L. Insulin resistance, central obesity, and risk of colorectal adenomas. Cancer 2012;118:1774-81.
12. Misciagna G, De Michele G, Guerra V, Cisternino AM, Di Leo A, Freudenheim JL; INTEROSP Group. Serum fructosamine and colorectal adenomas. Eur J Epidemiol 2004;19:425-32.
13. Yamada K, Araki S, Tamura M, Sakai I, Takahashi Y, Kashihara H, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998;27:794-8.
14. Yang MH, Rampal S, Sung J, Choi YH, Son HJ, Lee JH, et al. The association of serum lipids with colorectal adenomas. Am J Gastroenterol 2013;108:833-41.
15. Bayerdörffer E, Mannes GA, Richter WO, Ochsenkühn T, Seeholzer G, Köpcke W, et al. Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med 1993;118:481-7.
16. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2011;60:1094-102.
17. Jung YS, Ryu S, Chang Y, Yun KE, Park JH, Kim HJ, et al. Associations between parameters of glucose and lipid metabolism and risk of colorectal neoplasm. Dig Dis Sci 2015;60:2996-3004.
18. Taniguchi L, Higurashi T, Uchiyama T, Kondo Y, Uchida E, Uchiyama S, et al. Metabolic factors accelerate colorectal adenoma recurrence. BMC Gastroenterol 2014;14:187.
19. Jacobs ET, Martínez ME, Alberts DS, Jiang R, Lance P, Lowe KA, et al. Association between body size and colorectal adenoma recurrence. Clin Gastroenterol Hepatol 2007;5:982-90.
20. Laiyemo AO, Doubeni C, Badurdeen DS, Murphy G, Marcus PM, Schoen RE, et al. Obesity, weight change, and risk of adenoma recurrence: a prospective trial. Endoscopy 2012;44:813-8.
21. So H, Han S, Park HW, Kim EH, Lee JY, Lee HS, et al. Metabolic factors affect the occurrence of colorectal neoplasm on surveillance colonoscopies. J Gastroenterol Hepatol 2016;31:1273-9.
22. Chiu HM, Lee, YCTu, CHChang LC, Hsu WF, Chou CK, et al. Effects of metabolic syndrome and findings from baseline colonoscopies on occurrence of colorectal neoplasms. Clin Gastroenterol Hepatol 2015;13:1134-42.
23. Lin CC, Huang KW, Luo JC, Wang YW, Hou MC, Lin HC, et al. Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. J Chin Med Assoc 2014;77:508-12.
24. Kim MC, Jung SW, Kim CS, Chung TH, Yoo CI, Park NH. Metabolic syndrome is associated with increased risk of recurrent colorectal adenomas in Korean men. Int J Obes (Lond) 2012;36:1007-11.
25. Park HW, Byeon JS, Yang SK, Kim HS, Kim WH, Kim TI, et al. Colorectal neoplasm in asymptomatic average-risk Koreans: the KASID prospective multicenter colonoscopy survey. Gut Liver 2009;3:35-40.
26. Kitahara CM, Berndt SI, de González AB, Coleman HG, Schoen RE, Hayes RB, et al. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 2013; 31:2450-9.
27. Ng SC, Wong SH. Colorectal cancer screening in Asia. Br Med Bull 2013;105:29-42.
28. Hsu YC, Chiu HM, Liou JM, Chang CC, Lin JT, Liu HH, et al. Glycated hemoglobin A1c is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. Cancer Causes Control 2012;23:321-8.
29. Kim BJ, Kim YH, Sinn DH, Kang KJ, Kim JY, Chang DK, et al. Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males. Cancer Causes Control 2010;21:939-44.
30. Sasaki Y, Takeda H, Sato T, Orii T, Nishise S, Nagino K, et al. Serum Interleukin-6, insulin, and HOMA-IR in male individuals with colorectal adenoma. Clin Cancer Res 2012;18:392-9.
31. Otani T, Iwasaki M, Ikeda S, Kozu T, Saito H, Mutoh M, et al. Serum triglycerides and colorectal adenoma in a case-control study among cancer screening examinees (Japan). Cancer Causes Control 2006; 17:1245-52.
32. Sun ZJ, Huang, YHWu, JSYang YC, Chang, YFLu FH, et al. The association of serum lipids with the histological pattern of rectosigmoid adenoma in Taiwanese adults. BMC Gastroenterol 2011;11:54.
33. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013;104: 9-14.
34. Esteve E, Ricart W, Fernández-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005; 24:16-31.
35. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006;169:1505-22.
36. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583.
37. Liu Y, Tang W, Wang J, Xie L, Li T, He Y, et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control 2014;25:237-49.
38. Kim YH, Noh R, Cho SY, Park SJ, Jeon SM, Shin HD, et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Intest Res 2015;13:145-52.
39. Cho YH, Ko BM, Kim SH, Myung YS, Choi JH, Han JP, et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res 2014;12:139-45.
40. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal adenomatous polyps. Int J Colorectal Dis 2013;28:469-76.
41. Marks AR, Pietrofesa RA, Jensen CD, Zebrowski A, Corley DA, Doubeni CA. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2015;24:1692-8.